EQ vs. KZR, PRLD, OMER, ZVRA, IVA, GLSI, PBYI, RNAC, TRVI, and CAPR
Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Kezar Life Sciences (KZR), Prelude Therapeutics (PRLD), Omeros (OMER), Zevra Therapeutics (ZVRA), Inventiva (IVA), Greenwich LifeSciences (GLSI), Puma Biotechnology (PBYI), Cartesian Therapeutics (RNAC), Trevi Therapeutics (TRVI), and Capricor Therapeutics (CAPR). These companies are all part of the "pharmaceutical preparations" industry.
Kezar Life Sciences (NASDAQ:KZR) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.
Kezar Life Sciences has a net margin of 0.00% compared to Kezar Life Sciences' net margin of -32.01%. Equillium's return on equity of -47.28% beat Kezar Life Sciences' return on equity.
Kezar Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by insiders. Comparatively, 30.3% of Equillium shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Kezar Life Sciences received 100 more outperform votes than Equillium when rated by MarketBeat users. However, 82.93% of users gave Equillium an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
Equillium has higher revenue and earnings than Kezar Life Sciences. Equillium is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Equillium had 4 more articles in the media than Kezar Life Sciences. MarketBeat recorded 6 mentions for Equillium and 2 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.23 beat Equillium's score of 0.94 indicating that Equillium is being referred to more favorably in the news media.
Kezar Life Sciences currently has a consensus target price of $11.00, indicating a potential upside of 1,485.01%. Equillium has a consensus target price of $3.90, indicating a potential upside of 160.00%. Given Equillium's higher probable upside, analysts plainly believe Kezar Life Sciences is more favorable than Equillium.
Summary
Equillium beats Kezar Life Sciences on 11 of the 18 factors compared between the two stocks.
Get Equillium News Delivered to You Automatically
Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Equillium Competitors List
Related Companies and Tools
